Company provides initial outlook for Q1 and FY
2025
Nu Skin Enterprises Inc. (NYSE: NUS) today announced fourth
quarter and full-year 2024 results above its latest revenue
guidance.
Executive Summary Q4 2024 vs. Prior-year
Quarter
Revenue
$445.6 million; (8.8)%
- (4.1)% FX impact or $(20.1) million
- Rhyz revenue $83.1 million; 27.7%
Earnings Per Share
(EPS)
$(0.73) or $0.38 excluding restructuring
and other charges, compared to $0.15 or $0.37 excluding
restructuring and other charges
Customers
831,972; (15)%
Paid Affiliates
144,874; (13)% or (12)% excluding an
adjustment to eligibility requirements
Sales Leaders
36,912; (16)%
Executive Summary 2024 vs. 2023
Revenue:
$1.73 billion; (12.0)%
- (3.8)% FX impact or $(76.1) million
- Rhyz revenue $286.6 million; 32.3%
Earnings Per Share
(EPS):
$(2.95) or $0.84 excluding restructuring
and other charges, compared to $0.17 or $1.85 excluding inventory
write-off and other charges
“We were pleased to beat our fourth quarter revenue guidance,
generate sequential revenue growth and exceed our adjusted earnings
as we materially completed our restructuring plan," said Ryan
Napierski, Nu Skin president and CEO. “As we look ahead to 2025, we
anticipate improving business trends and a return to year-over-year
growth in several of our markets but also anticipate continued
economic challenges and poor consumer sentiment, particularly in
Greater China and South Korea.
“This year we will focus on strengthening our core Nu Skin
business with the continued rollout of our enhanced sales
performance compensation plan in several markets as well as
accelerating growth in developing markets including Latin America,”
continued Napierski. “We are also excited for Prysm iO™, an
exclusive intelligent wellness device that will provide consumers
with the nutritional insights needed to look, live and feel better.
We anticipate the introduction later this year of this breakthrough
technology will infuse energy and future growth for the nutrition
side of the business. Also, we were pleased with the strategic
transaction of Mavely for $250 million, which strengthened our
balance sheet and underscored the value of Rhyz to incubate and
scale meaningful business, as we continue to invest in and advance
our Rhyz segments.”
Q4 2024 Year-over-year Operating Results
Revenue
$445.6 million compared to $488.6
million
- (4.1)% FX impact or $(20.1) million
- Rhyz revenue $83.1 million; 27.7%
Gross Margin
62.7% or 71.4% excluding inventory
write-off compared to 72.1%
- Nu Skin business was 67.5% or 76.6% excluding inventory
write-off compared to 77.4%
Selling Expenses
37.1% compared to 37.1%
- Nu Skin business was 40.3% compared to 40.8%
G&A Expenses
27.1% compared to 29.7%
Operating Margin
(11.9)% or 7.7% excluding restructuring
and other charges compared to 3.3% or 6.4% excluding restructuring
and other charges
Interest Expense
$5.9 million compared to $7.4 million
Other Income
$1.1 million compared to $0.6 million
Income Tax Rate
37.5% or 36.6% excluding restructuring and
other charges compared to 21.9% or 24.9% excluding restructuring
and other charges
EPS
$(0.73) or $0.38 excluding restructuring
and other charges compared to $0.15 or $0.37 excluding
restructuring and other charges
Stockholder Value
Dividend Payments
$3.0 million
Stock Repurchases
$0.0 million
- $162.4 million remaining in authorization
Q1 and Full-year 2025 Outlook
Q1 2025 Revenue
$345 to $365 million; (17)% to (13)%
- Approximately (3)% FX impact
Q1 2025 EPS
$2.65 to $2.75 or $0.10 to $0.20 excluding
the gain from the Mavely transaction
2025 Revenue
$1.48 to $1.62 billion; (15)% to (6)% or
(11)% to (3)% excluding Mavely revenue in 2024
- Approximately (3)% FX impact
2025 EPS
$3.45 to $3.85 or $0.90 to $1.30 excluding
the gain from the Mavely transaction
“We are encouraged by our recent progress in strengthening our
business by driving sequential growth in our core Nu Skin business,
improving operational efficiencies and delivering strong cash
flow,” said James D. Thomas, chief financial officer. “As we look
ahead to 2025, our annual revenue guidance is $1.48 to $1.62
billion, with an approximate 3% foreign currency headwind. We
anticipate reported EPS of $3.45 to $3.85 and growth in our
adjusted EPS, which we estimate to be $0.90 to $1.30, excluding the
gain from the sale of Mavely. For the first quarter, which is
typically our lowest quarter due to seasonality of our business, we
project revenue of $345 to $365 million. This assumes a negative
foreign currency impact of approximately 3%, with reported earnings
per share of $2.65 to $2.75 or $0.10 to $0.20, excluding the gain
from the sale of Mavely. As we’ve executed on our restructuring
plan and improved our cost structure, we are better positioned to
execute our strategy and drive earnings growth in 2025.”
Conference Call
The Nu Skin Enterprises management team will host a conference
call with the investment community today at 5 p.m. (ET). Those
wishing to access the webcast, as well as the financial information
presented during the call, can visit the Investor Relations page on
the company's website at ir.nuskin.com. A replay of the webcast
will be available on the same page through Feb. 27, 2025.
About Nu Skin Enterprises Inc.
The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies
includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and
wellness company, powered by a dynamic affiliate opportunity
platform, which operates in nearly 50 markets worldwide. Backed by
40 years of scientific research, the company’s products help people
look, feel and live their best with brands including Nu Skin®
personal care, Pharmanex® nutrition and ageLOC® anti-aging, which
includes an award-winning line of beauty device systems. Formed in
2018, Rhyz is a synergistic ecosystem of consumer, technology and
manufacturing companies focused on innovation within the beauty,
wellness and lifestyle categories.
Important Information Regarding Forward-Looking
Statements: This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that represent the company’s current
expectations and beliefs. All statements other than statements of
historical fact are “forward-looking statements” for purposes of
federal and state securities laws and include, but are not limited
to, statements of management’s expectations regarding the macro
environment, business trends, the company’s performance, growth and
growth opportunities, investments, initiatives, rollout of the
enhanced sales performance compensation plan, new product
introductions, and performance of our Rhyz segments; projections
regarding revenue, expenses, tax rates, earnings per share, foreign
currency fluctuations, uses of cash and other financial items;
statements of belief; and statements of assumptions underlying any
of the foregoing. In some cases, you can identify these statements
by forward-looking words such as “believe,” “expect,” “anticipate,”
“accelerate,” “vision,” “continue,” “outlook,” “guidance,”
“improve,” “will,” “would,” “could,” “may,” “might,” the negative
of these words and other similar words.
The forward-looking statements and related assumptions involve
risks and uncertainties that could cause actual results and
outcomes to differ materially from any forward-looking statements
or views expressed herein. These risks and uncertainties include,
but are not limited to, the following:
- any failure of current or planned initiatives or products to
generate interest among the company’s sales force and customers and
generate sponsoring and selling activities on a sustained
basis;
- risk that direct selling laws and regulations in any of the
company’s markets, including the United States and Mainland China,
may be modified, interpreted or enforced in a manner that results
in negative changes to the company’s business model or negatively
impacts its revenue, sales force or business, including through the
interruption of sales activities, loss of licenses, increased
scrutiny of sales force actions, imposition of fines, or any other
adverse actions or events;
- economic conditions and events globally;
- competitive pressures in the company’s markets;
- risk that epidemics and related disruptions, or other crises
could negatively impact our business;
- adverse publicity related to the company’s business, products,
industry or any legal actions or complaints by the company’s sales
force or others;
- political, legal, tax and regulatory uncertainties, including
trade policies, associated with operating in Mainland China and
other international markets;
- uncertainty regarding meeting restrictions and other government
scrutiny in Mainland China, as well as negative media and consumer
sentiment in Mainland China on our business operations and
results;
- risk of foreign-currency fluctuations and the currency
translation impact on the company’s business associated with these
fluctuations;
- uncertainties regarding the future financial performance of the
businesses the company has acquired;
- risks related to accurately predicting, delivering or
maintaining sufficient quantities of products to support planned
initiatives or launch strategies, and increased risk of inventory
write-offs if the company over-forecasts demand for a product or
changes its planned initiatives or launch strategies;
- regulatory risks associated with the company’s products, which
could require the company to modify its claims or inhibit its
ability to import or continue selling a product in a market if the
product is determined to be a medical device or if the company is
unable to register the product in a timely manner under applicable
regulatory requirements; and
- the company’s future tax-planning initiatives, any prospective
or retrospective increases in duties or tariffs on the company’s
products imported into the company’s markets outside of the United
States, and any adverse results of tax audits or unfavorable
changes to tax laws in the company’s various markets.
The company’s financial performance and the forward-looking
statements contained herein are further qualified by a detailed
discussion of associated risks set forth in the documents filed by
the company with the Securities and Exchange Commission. The
forward-looking statements set forth the company’s beliefs as of
the date that such information was first provided, and the company
assumes no duty to update the forward-looking statements contained
in this release to reflect any change except as required by
law.
Non-GAAP Financial Measures: Constant-currency revenue
change is a non-GAAP financial measure that removes the impact of
fluctuations in foreign-currency exchange rates, thereby
facilitating period-to-period comparisons of the company’s
performance. It is calculated by translating the current period’s
revenue at the same average exchange rates in effect during the
applicable prior-year period and then comparing that amount to the
prior-year period’s revenue. The company believes that
constant-currency revenue change is useful to investors, lenders
and analysts because such information enables them to gauge the
impact of foreign-currency fluctuations on the company’s revenue
from period to period.
Earnings per share, gross margin, operating margin and income
tax rate, each excluding inventory write-off charges, restructuring
charges, the gain from the Mavely sale, and/or other charges, as
well as revenue growth rate excluding Mavely 2024 revenue, also are
non-GAAP financial measures.
- Inventory write-off charges and restructuring charges are not
part of the ongoing operations of our underlying business;
- Mavely revenue is no longer included in our operations
following our sale of this business on January 2, 2025; and
- the gain from the Mavely sale, legal accrual, and non-recurring
foreign tax charge that have been excluded in the non-GAAP
financial measures are not typical for our ongoing operations.
The company believes that these non-GAAP financial measures are
useful to investors, lenders and analysts because removing the
impact of these items facilitates period-to-period comparisons of
the company’s performance. Please see the reconciliations of these
items to our earnings per share, gross margin, operating margin,
income tax rate and revenue growth rate calculated under GAAP,
below.
The following table sets forth revenue for the three-month
periods ended December 31, 2024, and 2023 for each of our
reportable segments (U.S. dollars in thousands):
Three Months Ended
December 31,
Constant-Currency
2024
2023
Change
Change
Nu Skin
Americas
$
85,356
$
97,753
(12.7)%
3.8%
Southeast Asia/Pacific
64,925
66,889
(2.9)%
(3.4)%
Mainland China
56,438
71,516
(21.1)%
(21.2)%
Japan
47,512
50,966
(6.8)%
(3.8)%
Europe & Africa
42,600
47,892
(11.0)%
(10.1)%
South Korea
33,423
48,380
(30.9)%
(26.7)%
Hong Kong/ Taiwan
32,549
41,209
(21.0)%
(20.0)%
Other
(354)
(1,066)
66.8%
67.0%
Total Nu Skin
362,449
423,539
(14.4)%
(9.7)%
Rhyz
Manufacturing
47,882
50,363
(4.9)%
(4.9)%
Rhyz Other
35,221
14,738
139.0%
139.0%
Total Rhyz
83,103
65,101
27.7%
27.7%
Total
$
445,552
$
488,640
(8.8)%
(4.7)%
The following table sets forth revenue for the years ended
December 31, 2024, and 2023 for each of our reportable segments
(U.S. dollars in thousands):
Year Ended
December 31,
Constant-Currency
2024
2023
Change
Change
Nu Skin
Americas
$
322,516
$
398,222
(19.0)%
(8.2)%
Southeast Asia/Pacific
244,846
267,206
(8.4)%
(6.4)%
Mainland China
235,235
298,079
(21.1)%
(19.7)%
Japan
181,557
207,833
(12.6)%
(5.9)%
Europe & Africa
164,164
192,352
(14.7)%
(14.6)%
South Korea
163,706
236,099
(30.7)%
(27.7)%
Hong Kong/ Taiwan
130,610
153,589
(15.0)%
(13.3)%
Other
2,832
(858)
430.1%
430.3%
Total Nu Skin
1,445,466
1,752,522
(17.5)%
(13.2)%
Rhyz
Manufacturing
201,430
181,395
11.0%
11.0%
Rhyz Other
85,188
35,214
141.9%
141.9%
Total Rhyz
286,618
216,609
32.3%
32.3%
Total
$
1,732,084
$
1,969,131
(12.0)%
(8.2)%
The following table provides information concerning the number
of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin
business for the three-month periods ended December 31, 2024, and
2023:
Three Months Ended
December 31,
2024
2023
Change
Customers
Americas
227,556
231,183
(2)%
Southeast Asia/Pacific
82,956
106,471
(22)%
Mainland China
150,731
207,276
(27)%
Japan
110,069
113,670
(3)%
Europe & Africa
133,306
163,178
(18)%
South Korea
81,301
103,151
(21)%
Hong Kong/Taiwan
46,053
52,110
(12)%
Total Customers
831,972
977,039
(15)%
Paid Affiliates
Americas
28,361
31,910
(11)%
Southeast Asia/Pacific(1)
26,310
34,404
(24)%
Mainland China
22,125
25,889
(15)%
Japan
22,318
22,417
—
Europe & Africa
16,860
18,888
(11)%
South Korea(1)
17,939
22,166
(19)%
Hong Kong/Taiwan
10,961
11,212
(2)%
Total Paid Affiliates
144,874
166,886
(13)%
Sales Leaders
Americas
6,778
7,126
(5)%
Southeast Asia/Pacific
5,288
6,418
(18)%
Mainland China
8,969
11,296
(21)%
Japan
6,780
7,086
(4)%
Europe & Africa
3,343
3,968
(16)%
South Korea
3,343
5,249
(36)%
Hong Kong/Taiwan
2,411
2,916
(17)%
Total Sales Leaders
36,912
44,059
(16)%
(1) The December 31, 2024, number is affected by a change in
eligibility requirements for receiving certain rewards within our
compensation structure, to more narrowly focus on those affiliates
who are actively building a consumer base. We plan to implement
these changes in additional segments over the next several
quarters. We estimate the change in eligibility requirements
resulted in a reduction of approximately 1 thousand for Southeast
Asia/Pacific and South Korea.
- “Customers” are persons who have purchased directly from the
Company during the three months ended as of the date indicated. Our
Customer numbers include members of our sales force who made such a
purchase, including Paid Affiliates and those who qualify as Sales
Leaders, but they do not include consumers who purchase directly
from members of our sales force.
- “Paid Affiliates” are any Brand Affiliates, as well as members
of our sales force in Mainland China, who earned sales compensation
during the three-month period. In all of our markets besides
Mainland China, we refer to members of our independent sales force
as “Brand Affiliates” because their primary role is to promote our
brand and products through their personal social networks.
- “Sales Leaders” are the three-month average of our monthly
Brand Affiliates, as well as sales employees and independent
marketers in Mainland China, who achieved certain qualification
requirements as of the end of each month of the quarter.
NU SKIN ENTERPRISES,
INC.
Consolidated Statements of
Income (Unaudited)
(U.S. dollars in thousands,
except per share amounts)
Three Months Ended
December 31,
Year Ended
December 31,
2024
2023
2024
2023
Revenue
$
445,552
$
488,640
$
1,732,084
$
1,969,131
Cost of sales
166,405
136,215
550,233
611,850
Gross profit
279,147
352,425
1,181,851
1,357,281
Operating expenses:
Selling expenses
165,422
181,326
652,039
742,365
General and administrative expenses
120,930
145,033
479,037
546,858
Restructuring and impairment expenses
45,876
10,003
202,360
19,790
Total operating expenses
332,228
336,362
1,333,436
1,309,013
Operating income (loss)
(53,081)
16,063
(151,585)
48,268
Interest expense
5,864
7,368
26,409
25,560
Other income, net
1,143
633
2,943
3,870
Income (loss) before provision for income
taxes
(57,802)
9,328
(175,051)
26,578
Provision (benefit) for income taxes
(21,697)
2,046
(28,457)
17,983
Net income (loss)
$
(36,105)
$
7,282
$
(146,594)
$
8,595
Net income (loss) per share:
Basic
$
(0.73)
$
0.15
$
(2.95)
$
0.17
Diluted
$
(0.73)
$
0.15
$
(2.95)
$
0.17
Weighted-average common shares outstanding
(000s):
Basic
49,712
49,411
49,662
49,711
Diluted
49,712
49,479
49,662
49,860
NU SKIN ENTERPRISES,
INC.
Consolidated Balance Sheets
(Unaudited)
(U.S. dollars in thousands)
December 31,
2024
2023
ASSETS
Current assets
Cash and cash equivalents
$
186,883
$
256,057
Current investments
11,111
11,759
Accounts receivable, net
50,784
58,695
Inventories, net
190,242
279,978
Prepaid expenses and other
72,643
81,066
Current assets held for sale
26,936
14,316
Total current assets
538,599
701,871
Property and equipment, net
379,595
432,965
Operating lease right-of-use assets
72,605
90,107
Goodwill
83,625
218,166
Other intangible assets, net
74,278
95,260
Other assets
298,008
247,606
Long-term assets held for sale
22,204
22,651
Total assets
$
1,468,914
$
1,808,626
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities
Accounts payable
$
34,880
$
43,113
Accrued expenses
217,808
253,702
Current portion of long-term debt
30,000
25,000
Current liabilities held for sale
13,919
7,056
Total current liabilities
296,607
328,871
Operating lease liabilities
58,439
70,943
Long-term debt
363,613
478,040
Other liabilities
97,475
106,641
Long-term liabilities held for sale
1,325
2,163
Total liabilities
817,459
986,658
Commitments and contingencies
Stockholders’ equity
Class A common stock – 500 million shares
authorized, $0.001 par value, 90.6 million shares issued
91
91
Additional paid-in capital
627,787
621,853
Treasury stock, at cost – 40.8 million and
41.1 million shares
(1,563,614)
(1,570,440)
Accumulated other comprehensive loss
(124,758)
(100,006)
Retained earnings
1,711,949
1,870,470
Total stockholders’ equity
651,455
821,968
Total liabilities and stockholders’
equity
$
1,468,914
$
1,808,626
NU SKIN ENTERPRISES, INC.
Reconciliation of Gross Margin Excluding Impact of Inventory
Write-off to GAAP Gross Margin (in thousands, except for
percentages)
Three months ended December
31,
Year ended December
31,
2024
2023
2024
2023
Gross Profit
$
279,147
$
352,425
$
1,181,851
$
1,357,281
Impact of inventory write-off
38,765
-
38,765
65,728
Adjusted Gross Profit
$
317,912
$
352,425
$
1,220,616
$
1,423,009
Gross Margin
62.7%
72.1%
68.2%
68.9%
Gross Margin, excluding inventory
write-off impact
71.4%
72.1%
70.5%
72.3%
Revenue
$
445,552
$
488,640
$
1,732,084
$
1,969,131
NU SKIN ENTERPRISES, INC.
Reconciliation of Core Nu Skin Business Gross Margin Excluding
Impact of Inventory Write-off to GAAP Gross Margin (in
thousands, except for percentages)
Three months ended December
31,
2024
2023
Gross Profit
$
244,754
$
327,786
Impact of inventory write-off
32,704
-
Adjusted Gross Profit
$
277,458
$
327,786
Gross Margin
67.5%
77.4%
Gross Margin, excluding inventory
write-off impact
76.6%
77.4%
Revenue
$
362,449
$
423,539
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Impact of Certain
Charges to GAAP Operating Margin (in thousands, except for
percentages)
Three months ended December
31,
Year ended December
31,
2024
2023
2024
2023
Operating Income
$
(53,081)
$
16,063
$
(151,585)
$
48,268
Impact of inventory write-off
38,765
-
38,765
65,728
Impact of restructuring and impairment
45,876
10,003
202,360
19,790
Impact of other charges(1)
2,940
5,260
2,940
5,260
Adjusted operating income
$
34,500
$
31,326
$
92,480
$
139,046
Operating margin
(11.9)%
3.3%
(8.8)%
2.5%
Operating margin, excluding impact of
restructuring and other charges
7.7%
6.4%
5.3%
7.1%
Revenue
$
445,552
$
488,640
$
1,732,084
$
1,969,131
(1) Other charges for the fourth quarter and full year 2024
consist of transaction-related expenses incurred related to the
sale of Mavely. Other charges for the fourth quarter and full year
2023 consist of a legal contingency ($3.0 million) and a
non-recurring foreign tax charge ($2.3 million).
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Certain
Charges to GAAP Effective Tax Rate (in thousands, except for
percentages)
Three months ended December
31,
Year ended December
31,
2024
2023
2024
2023
Provision (benefit) for income taxes
$
(21,697)
$
2,046
$
(28,457)
$
17,983
Impact of restructuring on provision for
income taxes
32,604
4,081
55,674
7,324
Provision for income taxes, excluding
impact of restructuring
$
10,907
$
6,127
$
27,217
$
25,307
Income (loss) before provision for income
taxes
(57,802)
9,328
(175,051)
26,578
Impact of inventory write-off
38,765
-
38,765
65,728
Impact of restructuring and impairment
45,876
10,003
202,360
19,790
Impact of other charges(1)
2,940
5,260
2,940
5,260
Income before provision for income taxes,
excluding impact of restructuring and other charges
$
29,779
$
24,591
$
69,014
$
117,356
Effective tax rate
37.5%
21.9%
16.3%
67.7%
Effective tax rate, excluding impact of
restructuring and other charges
36.6%
24.9%
39.4%
21.6%
(1) Other charges for the fourth quarter and full year 2024
consist of transaction-related expenses incurred related to the
sale of Mavely. Other charges for the fourth quarter and full year
2023 consist of a legal contingency ($3.0 million) and a
non-recurring foreign tax charge ($2.3 million).
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain
Charges to GAAP Earnings Per Share (in thousands, except for
per share amounts)
Three months ended December
31,
Year ended December
31,
2024
2023
2024
2023
Net income
$
(36,105)
$
7,282
$
(146,594)
$
8,595
Impact of Inventory Write-off:
Inventory write-off
38,765
-
38,765
65,728
Tax impact
(14,643)
-
(14,643)
(4,866)
Impact of restructuring and impairment
expense:
Restructuring and impairment
45,876
10,003
202,360
19,790
Tax impact
(17,329)
(3,088)
(40,399)
(1,465)
Impact of other charges(1)
Impact of other charges
2,940
5,260
2,940
5,260
Tax impact
(632)
(993)
(632)
(993)
Adjusted net income
$
18,872
$
18,464
$
41,797
$
92,049
Diluted earnings per share
$
(0.73)
$
0.15
$
(2.95)
$
0.17
Diluted earnings per share, excluding
impact of restructuring and other charges
$
0.38
$
0.37
$
0.84
$
1.85
Weighted-average common shares outstanding
(000)
49,712
49,479
49,662
49,860
(1) Other charges for the fourth quarter and full year 2024
consist of transaction-related expenses incurred related to the
sale of Mavely. Other charges for the fourth quarter and full year
2023 consist of a legal contingency ($3.0 million) and a
non-recurring foreign tax charge ($2.3 million).
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely
Sale to GAAP Earnings Per Share
Three months ended March 31,
2025
Year ended December 31,
2025
Low end
High end
Low end
High end
Earnings Per Share
$
2.65
$
2.75
$
3.45
$
3.85
Impact of Mavely Sale:
Pre-tax Mavely sale gain
(3.40)
(3.40)
(3.40)
(3.40)
Tax impact
0.85
0.85
0.85
0.85
Adjusted EPS
$
0.10
$
0.20
$
0.90
$
1.30
NU SKIN ENTERPRISES, INC.
Reconciliation of Revenue Growth Rates Excluding Mavely 2024
Revenue to GAAP Revenue Growth Rates
(in thousands, except for
percentages)
Three months ended March 31,
2025
Year ended December 31,
2025
Low end
High end
Low end
High end
2024 Revenue
$
417,306
$
417,306
$
1,732,084
$
1,732,084
Less: Mavely 2024 Revenue
6,970
6,970
69,620
69,620
2024 Revenue, excluding Mavely
$
410,336
$
410,336
$
1,662,464
$
1,662,464
Revenue Growth Rate
(17)%
(13)%
(15)%
(6)%
Revenue Growth Rate, excluding Mavely 2024
Revenue
(16)%
(11)%
(11)%
(3)%
2025 Forecasted Revenue
$
345,000
$
365,000
$
1,480,000
$
1,620,000
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250213536488/en/
Media: media@nuskin.com, (801) 345-6397 Investors:
investorrelations@nuskin.com, (801) 345-3577
Nu Skin Enterprises (NYSE:NUS)
Historical Stock Chart
From Jan 2025 to Feb 2025
Nu Skin Enterprises (NYSE:NUS)
Historical Stock Chart
From Feb 2024 to Feb 2025
